William D. Turner - Feb 7, 2022 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Role
Chief Reg & Tech Ops Officer
Signature
/s/ William D. Turner / By: Mary Christina Thomson, Attorney-In-Fact
Stock symbol
SRRA
Transactions as of
Feb 7, 2022
Transactions value $
-$202,725
Form type
4
Date filed
2/8/2022, 03:03 PM
Previous filing
Jan 28, 2022
Next filing
Mar 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRRA Common Stock Options Exercise $121K +10K $12.05 10K Feb 7, 2022 Direct
transaction SRRA Common Stock Sale -$323K -10K -100% $32.32 0 Feb 7, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRRA Stock Option (Right to Buy) Options Exercise $0 +10K $0.00* 0 Feb 7, 2022 Common Stock 10K $12.05 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2022. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement.
F2 On August 4, 2021, the option vested as to 25% of the total shares granted on August 4, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.